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INTRODUCTION
Endothelial cells, which line the inner lumen of blood vessels, are the primary determinants vascular barrier function. During episodes of infection, ischemic or traumatic injury, endothelial cells are primary targets for leukocytes and can result in altered barrier function (1) . Under such pathological conditions, endothelial metabolism, gene expression, and cell surface protein expression may be altered by a myriad of soluble factors, including cytokines, bioactive lipids, and bacterial endotoxin (1) . Similarly, vascular barrier function may be altered by the local release of soluble mediators from activated polymorphonuclear leukocytes (PMN). For example, it is only recently appreciated that PMN-derived compounds, such as adenosine, may provide endogenous pathways to dampen changes in endothelial permeability during leukocyte extravasation (2) . These same studies suggested the existence of other unknown PMN-derived which might influence endothelial barrier properties.
Within the central nervous system (CNS), glutamate is the primary excitatory neurotransmitter.
Four classes of glutamate receptors have been identified, including alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropioninc acid (AMPA), kainate, N-methyl-D-aspartate (NMDA) and the more recently described metabotropic glutamate receptors (mGluR) (3) . mGluR are single polypeptide chain receptors characterized by a seven transmembrane spanning structure and a long amino-terminal extracellular domain important in Glu binding (4) . Coupled to guanosine triphosphate (GTP)-binding proteins, mGluR form a family of at least 8 subtypes which are classified into 3 groups based on sequence homology, pharmacological profile of activation and signal transduction pathways (5) .
which have been utilized in similar endothelial permeability models (9, 10) . Monolayers were stirred via a rotating platform (60 rotations/min, Clinical Rotator, Fisher) and serosal fluid from each well was sampled (50 µl) over 60. Sample volume was replaced with HBSS. Fluorescence intensity (excitation, 485 nm; emission, 530 nm) of each sample was measured (Cytofluor 2300, Millipore Corp., Bedford, MA) and FITC-dextran concentrations determined from standard curves generated by serial dilution of FITC-dextran. Paracellular flux was calculated by linear regression of sample fluorescence. Consistent with previous reports, control experiments demonstrated decreased permeability with forskolin and 8-bromo-cAMP (11) , and increased permeability with thrombin and hydrogen peroxide (data not shown) (12) . HP 1100 diode array detector was used with a C18 reverse phase HPLC column (5µm, 4.6 x 250mm, Phenomenex, Torrance CA). Activated PMN-derived samples were eluted (1 ml fractions), evaporated to dryness, reconstituted in HBSS and assayed for influence on paracellular permeability.
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L-glutamic acid and glutamine were measured in cell-free PMN supernatants using a Na 2 HPO 4 (0.1 M), Na 2 EDTA (0.1 mM), pH 6.38 mobile phase (1.2 ml/min). Absorbance was measured at 460 and 275 nm. UV absorption spectra were obtained at chromatographic peaks. Lglutamic acid and glutamine were identified by their chromatographic behavior (e.g., retention time, UV absorption spectra, co-elution with standards) (13) .
Mass spectroscopy. For structural elucidation of L-glutamic acid and glutamine, bioactive materials eluted by HPLC were injected into a liquid chromatograph in tandem with a mass spectrometer (LC / MS) using an 2.1 x 100 mm ODS Hypersil column (Hewlett Packard). The LC/MS was run at 0.5 ml/min. Buffers were A= water with 0.1% formic acid, B = acetonitrile with 0.1% formic acid, with gradient set at 20.5% B to 75% B in 35 min using buffer A as a diluent. The mass spectrometer used was a Platform II (Micromass Instruments, Beverly, MA) operated using atmospheric pressure chemical ionization (ApCI) and operated such that scans of opposite polarity were obtained on alternating scans (alternating positive / negative ion mode). The instrument was scanned from mass 100 to 600 in 1 sec, with a 0.1sec interscan time. In this manner, full positive and negative ion mass spectra were obtained from a single chromatographic analysis.
RT-PCR and Sequencing of Human Endothelial mGluR. RT-PCR analysis of BMVEC
and HMVEC mRNA levels was performed using DNAse-treated total RNA as previously described (14) , and primers (Sigma-Genosys, The Woodlands, TX) specific for mGluR1 (forward primer 5'-GGG ACA GCA TAT GTG GCA C-3' and reverse primer 5'-ATG GAA GGG CTA CCA GGC-3', 213 bp fragment), mGluR2 (forward primer 5'-AAG TAT GTT GGG CTC GC-3' and reverse primer GGC AGT GTG TTC TTT CC-3' and reverse primer 5'-GAG CTT TTC CGC TGA TTG AG-3', 502   bp fragment), mGluR8 (forward primer 5'-GAC CGC CAA GTT CTA CTG GA-3' and reverse primer   5'-TCA CTT AGC TCT GGG GCT GT-3', 504 bp Water samples or RNA samples containing no reverse transcriptase were amplified in parallel to ensure that no contaminating DNA was present during PCR (data not shown).
Human Endothelial mGluR mRNA Sequencing and In Situ Hybridization. PCR products for human endothelial mGluR1, mGluR4 and mGluR5 were gel purified using a Qiagen gel extraction kit (Qiagen, Valencia, CA), ligated into a pGEM-T vector and transformed using the pGEM-T Easy vector system (Promega, Madison WI) according to the manufacturer's instructions. The predicted nucleotide sequence for each mGluR was confirmed by sequencing (Harvard sequencing core) several colonies from each mGluR ligation (data not shown). For probe production, EcoR1 digested fragments were gel purified using a Qiagen gel extraction kit (Qiagen, Valencia, CA) and labeled with biotin-16-dUTP, and the probes separated with spin columns.
For mGluR analysis by in situ hybridization, human BMVEC or HMVEC were grown to confluence on LabTech tissue culture microscope slides (Nalge Nunc International, Rochester, NY). The cells were incubated in 4x SSC-1% BSA with avidin-FITC (2 µg/ml) for 30 min and washed 3 times in 2x SSC at room temperature on a rotating shaker. The cells were mounted in antifade mounting medium, covered and viewed on a Leica confocal scanning microscope. Control BMVEC and HMVEC were incubated in RNAse A (100 µg/ml in 2x SSC for 1h at 37°C) to determine specificity of the probe for RNA. After incubation in RNAse A, the cells were hybridized as described above and incubated with avidin-FITC, washed and viewed by confocal microscopy. A second negative control preparation consisted of BMVEC and HMVEC hybridized with a porcine mannosebinding lectin cDNA probe, washed, then reacted with FITC-avidin and viewed on a confocal microscope. All in situ hybridization studies were done in triplicate.
Immunofluorescence. Confluent human BMVEC and HMVEC grown on coverslips were washed in PBS, fixed in 1% paraformaldehyde / 100 mM cacodylate buffer for 10 min at room temperature and washed again. The coverslips were incubated with rabbit anti-mGluR1 (Upstate Biotechnology, Lake Placid, NY), mGluR4 or mGluR5 (Chemicon International, Temecula, CA) pAb for 1 hr at room temperature. After washing, the slips were incubated with FITC-conjugated goat antirabbit IgG (Sigma) or rhodamine-conjugated phalloidin (Molecular Probes, Eugene, OR). The coverslips were washed (x3; 10 min each), mounted with anti-fade mounting media (Molecular Probes, Eugene, OR), and analyzed with a Zeiss confocal microscope as previously described (15) . Controls incubated with FITC-conjugated goat anti-rabbit IgG only were processed as above, omitting the primary antibody to determine nonspecific binding. Additionally, some coverslips were incubated an irrelevant, isotype control rabbit anti-rat MBL pAb. All analyses were conducted at the same pinhole, voltage and laser settings. This experiment was performed three times (n=3). 
Blood Brain Barrier (BBB) Permeability in Hypoxic Mice. Alterations in BBB permeability
in vivo were determined in a hypoxic mouse model (17) . As guided by previous in vivo studies using mGluR agonists and antagonists in rodents (18, 19) , eight-week-old C57 black mice (Taconic, Data analyses were performed using Sigma Stat (Jandel Scientific, San Rafael, CA). A p value of < 0.05 was considered significant. Transendothelial FITC-dextran flux across endothelial monolayers was normalized to untreated cells and analyzed by one-or two-way analysis of variance (ANOVA).
All pairwise multiple comparisons were made using the Student-Newman-Keuls test. FITC-dextran flux across the BBB in hypoxic mice is presented as a permeability index calculated as the ratio of measured brain to serum fluorescence.
RESULTS

Soluble Supernatants Derived from Activated PMN Regulate Endothelial Barrier
Function. We have previously demonstrated that upon activation, PMN release AMP and adenosine, which through activation of surface adenosine receptors, provides a resealing mechanism during PMN transendothelial migration (2) . Here, we pursued the existence of additional pathways for regulation of barrier function by PMN. Initial studies were undertaken to screen supernatants derived from FMLP To identify potentially novel, barrier-influencing molecules, supernatants derived from activated PMN (FMLP 10 -8 M, 1hr) were fractionated by HPLC, concentrated 20-fold and screened for influences on HMVEC permeability. As shown in Figure 1B , this analysis revealed two major biologically active fractions, eluting in the time periods of 2-3 min (fraction 3, 85±9% decrease in permeability) and 8-9 min (fraction 9, 82±11% decrease in permeability), respectively. Further evaluation of fraction 9 identified it as 5'AMP (based on retenion time, UV spectra and co-eluton with standards, data not shown), as we have studied in the past (2) . Isolation and further purification of fraction 3 revealed this fraction to be stable to extremes in temperaure and pH, of low molecular mass (<1kD) with a dominant UV chromophore at 199nm, likely indicative of a saturated amine linkage (21) .
Identification of Fraction 3 as Glutamate.
We next employed mass spectroscopy to obtain structural insight into fraction 3. As shown in Figure 2A characteristics. HPLC experiments to define fraction 3 using internal standards of glutamine and glutamate did not provide the level of resolution necessary to distinguish betweeen these amino acids.
We thus resorted to derivatization of fraction 3 with dabsyl chloride (13) . As shown in Figure 2B , this approach allowed us to distinguish between glutamate and glutamine based on retention time, and revealed that purfied, dabsylated fraction 3 eluted with authentic glutamate, thus identifying this isolated, bioactive fraction as glutamate. A fMLP (10 -8 M) time course of glutamate release is shown in Figure 2C , and indicates that glutamate release is rapid (within 5 min.) and maximal by 45 Human Endothelia Express mGluR. Based on the above findings, we screened endothelia for the existence of mGluR's. Although evidence is rapidly accumulating that mGluR are expressed by a variety of cell types (5) , functional mGluR have not been described on human endothelia. Initial studies by RT-PCR revealed that endothelia express only mGluR1, mGluR4 and mGluR5 mRNA (BMVEC data shown in Fig. 4A ). Detectable transcripts for mGluR2, mGluR3, mGluR6, mGluR7, or mGluR8 were not evident, even at high PCR cycle numbers (>35 cycles). These data were confirmed by in situ hybridization, with both BMVEC and HMVEC staining positively for mGluR1, mGluR4 and mGluR5 (Fig. 4, lower panels A, B and C, respectively) . BMVEC and HMVEC hybridized with a control probe (porcine mannose-binding lectin) revealed no detectable binding, and as such, served as a negative control (Fig. 4, lower panel D) . To assess the relative levels of mGluR's in BMVEC and HMVEC, we employed semi-quantitative RT-PCR of mGluR1, mGluR4 and mGluR5 relative to β-actin. As shown in Figure 4E and F, this relative comparison revealed that while both BMVEC and HMVEC express mGluR1, 4 and 5, HMVEC express relatively more mGluR1 and 5 compared to BMVEC, and that each expresses approximately equal amounts of mGluR4 (see Figure 4F ).
Having demonstrated that human endothelia express mGluR mRNA, mGluR cell surface protein expression was investigated by immunofluorescence and by immunoprecipitation of biotinylated surface protein. Human endothelial mGluR expression was also confirmed by immunofluorescence. Consistent with our in situ hybridization results, non-permeabilized BMVEC and HMVEC stained positively for mGluR1, mGluR4 and mGluR5 (Fig. 4 , panels A, C and E, respectively), in which a surface distribution of mGluR was evident with dominant staining at the edge of the plasma membrane. BMVEC and HMVEC incubated with an irrelevant, isotype control rabbit anti-rat mannose-bindin lectin pAb (Fig. 4, panel G) or FITC-conjugated goat anti-rabbit IgG only (Fig. 5 , Panel I) revealed no demonstrable staining and thus, served as a negative control. In each case, rhodamine phalloidin staining was used to generally localize cells (Figures 5 B, D, F, H and J) . As shown in Figure 5K , streptavidin blot analysis of biotinylated human BMVEC immunoprecipitates under reduced conditions revealed 140, 102 and 140 kD bands consistent with the known MW of human mGluR1, mGluR4, and mGluR5, respectively (22, 23) . Taken together, these data confirm that human endothelia express group I and III mGluR mRNA and protein.
Glutamate-elicted Changes in Endothelial VASP Phosphorylation. We next attempted to gain insight into mechanism(s) of glutamate-regulated barrier function. It was recently shown that the EVH1 domain of the Homer protein family (Vesl-1s, Vesl-1L and Vesl-2) interacts with mGluR1 and mGluR5 via specific mGluR peptide sequence (TPPSPF) found in the N-terminus (24) . Vasodilator stimulated phosphoprotein (VASP) is an EVH1 domain-containing protein which serves as a negative regulator of actin dynamics (25), and we have recently shown that VASP phosphorylation is critical to cyclic nucleotide-induced promotion of endothelial barrier function (26). In addition, VASP has been implicated in the regulation of BMVEC cell-cell contacts and BBB permeability through inhibition of cell retraction (27). Therefore, using glutamate concentrations which most influence HMVEC (10µM) and BMVEC (0.1µM) barrier function (see Figure 3A) , we investigated the influence of glutamate on VASP phosphorylation in vitro. As shown in Figure 6A , western blot analysis of HMVEC lysates following exposure to glutamate (10µM), a concentration which promotes HMVEC barrier (see Figure 3A) , revealed dominant VASP phosphorylation (phosphorylation of serine at position 157 leads to a marked shift in apparent molecular mass of VASP by SDS-PAGE from 46 kDa to 50 kDa) (28) . Similarly, exposure of BMVEC to glutamate (0.1µM), a concentration which increases endothelial permeability (see Figure 3A) , resulted in a decreased basal VASP phosphorylation.
As an extension of these findings, we determined whether pharmacologic inhibition of glutamateregulated VASP phosphorylation manifest as changes in permeability. Phosphorylation of VASP in the serine 157 position is predominantly dependent on protein kinase A (29), and therefore, as shown in Figure 6B , the protein kinase A inhibitor H89 (10µM) inhibited glutamate-induced VASP phosphorylation and significantly dampened the increase in barrier associated with glutamate exposure (p<0.01 by ANOVA). Dephosphorylation of VASP is predominantly via protein phosphatase-2A (30), and therefore, as shown in Figure 6C , okadaic acid (10nM) was used to inhibit basal dephophorylation in BMVEC ( Figure 6A ) and assessed for permeability changes. As can be seen, these conditions resulted in a loss of glutamate-regulated barrier function in BMVEC (p<0.05 by ANOVA). Taken together, such data indicate that glutamate-regulated VASP phosphorylation parallels changes associated with endothelial permeability. mGluR Blockade Attenuates BBB Permeability following In Vivo Hypoxia. To further confirm these in vitro findings, the influence of mGluR therapy on BBB permeability was investigated in an in vivo hypoxic mouse model (17) . As shown in Figure 7A , a comparison of mice exposed to normoxia (21%O 2 , 4hr) and hypoxia (8%O 2 , 4hr) revealed a 9±0.4-fold increase in BBB permeability in hypoxia, and paralleled the accumulation of PMN within brain tissue (measured as myeloperoxidase activity, mean 5.5±0.6-fold increase in mice exposed to hypoxia). To examine the potential role of glutamate under these circumstances, mice were subjected to hypoxia and co- An unexpected aspect of this work revealed differential glutamate responses between BMVEC and HMVEC. Indeed, while both human BMVEC and HMVEC express similar mGluR subtypes, extracellular exposure to equimolar glutamate / selective mGluR agonsist concentrations resulted in differential responses (i.e. HMVEC and BAEC responded with significantly decreased permeability while BMVEC responded with increased permeability). At present, we do not know the underlying mechanism(s) of this differential response. Based on the findings that glutamate phosphorylates VASP in HMVEC and dephosphorylates VASP in BMVEC, it is possible that mGluR G-protein receptor coupling is different, with the likely possibility that the relative difference in expression of mGluR1 in HMVEC over BMVEC (see Figure 4F ) may more dominantly couple to G αs (i.e. elevation in intracellular cAMP) in response to glutamate and in BMVEC may be relative more G αi coupled (decrease in intracellular cAMP). It is equally possible that post-receptor events could explain these differences. A rapidly evolving idea suggests that endothelial cells from different anatomic locales may be phenotypically distinct (51) , and that cerebral endothelial cells may be quite distinct from most peripheral vascular endothelia (52). It is possible, for example, that microvascular endothelial cells express distinct isoforms of adenylyl cyclase compared to macrovascular endothelial cells, and that such differential expression of adenylyl cyclase may explain agonist selectivity for endothelial permeability in a regionally specific manner (46).
In addition to our observation that PMN-derived glutamate may alter endothelial barrier function, it should be noted that neuronal release of glutamate into the extracellular space following CNS hypoxia plays a key role in mediating ischemic brain damage by causing direct neurotoxicity (53) and increasing BBB permeability(54). We thus investigated the influence of mGluR therapy in regulating BBB permeability in an in vivo hypoxic mouse model. Initial studies indicated a relationship between PMN accumulation and increases in BBB permeability, providing at least the possiblity that PMN-derived glutamate might be a pathophysiologically-relevant mediator in vivo.
Extensions of these experiments indicated that pre-treatment of mice with a selective, group I (PHCCC) or III (CPPG) mGluR receptor antagonist significantly decreased BBB permeability following 4 hr of hypoxia compared to untreated mice. In contrast, mice pre-exposed to selective, group I (DHPG) or III (L-AP4) mGluR receptor agonist resulted in a small, but significant increase in BBB permeability following 4 hr of hypoxia or normoxia compared to untreated mice. These data suggest that glutamate-induced increases in BBB permeability following hypoxia are mediated, at least in part, by group I and III mGluR.
Taken together, these results suggest a a previously unappreciated pathway by which glutamate derived from activated PMN may regulate human vascular endothelial barrier function via its action on endothelial expressed mGluR's. Globally, such findings suggest that mGluR therapy may thus represent a novel therapeutic strategy for regulation of microvascular permeability in diverse tissues. 
